The Impact of the Mediterranean Diet and Lifestyle Intervention on Lipoprotein Subclass Profiles among Metabolic Syndrome Patients : Findings of a Randomized Controlled Trial
Candás-Estébanez, Beatriz (SCIAS-Barcelona Hospital)
Fernández-Cidón, Bárbara (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Corbella, Emili (Instituto de Salud Carlos III)
Tebé, Cristian (Institut d'Investigació Biomèdica de Bellvitge)
Fanlo-Maresma, Marta (Instituto de Salud Carlos III)
Esteve-Luque, Virginia (Instituto de Salud Carlos III)
Salas-Salvadó, Jordi (San Joan de Reus University Hospital)
Fitó, Montserrat (Institut Hospital del Mar d'Investigacions Mèdiques)
Riera Mestre, Antoni (Universitat de Barcelona)
Ros, Emilio (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Pintó, Xavier (Universitat de Barcelona)

Data:	2024
Resum:	Metabolic syndrome (MetS) is associated with alterations of lipoprotein structure and function that can be characterized with advanced lipoprotein testing (ADLT). The effect of the Mediterranean diet (MedDiet) and weight loss on the lipoprotein subclass profile has been scarcely studied. Within the PREDIMED-Plus randomized controlled trial, a sub-study conducted at Bellvitge Hospital recruiting center evaluated the effects of a weight loss program based on an energy-reduced MedDiet (er-MedDiet) and physical activity (PA) promotion (intervention group) compared with energy-unrestricted MedDiet recommendations (control group) on ADLT-assessed lipoprotein subclasses. 202 patients with MetS (n = 107, intervention; n = 95, control) were included. Lipid profiles were determined, and ADLT was performed at baseline, 6, and 12 months. Linear mixed models were used to assess the effects of intervention on lipoprotein profiles. Compared to the control diet, at 12 months, the er-MedDiet+PA resulted in a significant additional 4. 2 kg of body weight loss, a decrease in body mass index by 1. 4 kg/m 2, reduction in waist circumference by 2. 2 cm, decreased triglycerides, LDL-cholesterol and non-HDL-cholesterol, and increased HDL-cholesterol. In er-MedDiet+PA participants, ADLT revealed a decrease in small dense-LDL-cholesterol (sd-LDL-C), intermediate-density lipoproteins, VLDL-triglyceride, and HDL-Triglyceride, and an increase in large LDL and large VLDL particles. In conclusion, compared to an ad libitum MedDiet (control group), er-MedDiet+PA decreased plasma triglycerides and the triglyceride content in HDL and VLDL particles, decreased sd-LDL-C, and increased large LDL particles, indicating beneficial changes against cardiovascular disease.
Ajuts:	Ministerio de Economía y Competitividad PI16/01094 Instituto de Salud Carlos III PI19/01032
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Metabolic syndrome ; Mediterranean diet ; Lipoprotein precipitation ; Nuclear magnetic resonance lipid profile ; Advanced lipoprotein tests ; Small dense LDL
Publicat a:	International journal of molecular sciences, Vol. 25, Num. 2 (January 2024) , art. 1338, ISSN 1422-0067

DOI: 10.3390/ijms25021338
PMID: 38279337

16 p, 868.5 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats